MedPath

Investigation on the effectiveness and safety of lipid-lowering treatments in patients with familial hypercholesterolemia (FAME: Familial Hypercholesterolemia Expert Forum Trial)

Phase 4
Conditions
familial hypercholesterolemia
Registration Number
JPRN-UMIN000003211
Lead Sponsor
Osaka University Graduate School of Medicine
Brief Summary

762 heterozygous and 7 homozygous FH patients were enrolled. CAD was recorded in 23% of patients. Patients without CAD with LDL-C < 100mg/dL, 12.3% and those with CAD with < 70 mg/dL, 1.8%. Male gender, age > 40, FH score < 20, hypertension, and sibling CAD were significantly positively associated with CAD. Male gender, CAD at the baseline, and parental CAD were related to the development of atherosclerotic cardiovascular disease events.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
769
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients whose serum triglyceride level is over 400 mg/dl at the time of registration should be excluded. 2) Patients who are suffering from severe liver dysfunction (acute phase and decompensated cirrhosis) 3) Patients with dyslipidemia who are suffering from the following diseases (1) hypothyroidism (2) pancreatitis 4) Patients with uncontrolled diabetes mellitus, whose HbA1c level is over 9%. 5) Patients who are pregnant, suckling or likely to be pregnant. 6) Patients who are judged by the doctor to be improper to be enrolled in this study.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath